G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference
11 avr. 2023 12h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack...
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
01 mars 2023 06h30 HE
|
G1 Therapeutics
- Achieved $31.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2022, Representing 182% Growth Over 2021; Provided 2023 Net COSELA Revenue Guidance of $50 to $60 Million - -...
G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
28 févr. 2023 14h10 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on March 7th, 2023, at 10:30 AM EST,...
G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023
22 févr. 2023 10h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb. 22, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a...
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
13 févr. 2023 06h00 HE
|
G1 Therapeutics
- PRESERVE 1 Achieved its Co-Primary Endpoints Showing Statistically Significant Reductions in Occurrence of Severe Neutropenia During Induction and Duration of Severe Neutropenia in Cycles 1 Through...
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 févr. 2023 16h46 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...
G1 Therapeutics to Participate in the Virtual 2023 B. Riley Securities 3rd Annual Oncology Conference
11 janv. 2023 07h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 19th, 2023, at 11:30 AM...
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
09 janv. 2023 06h30 HE
|
G1 Therapeutics
- Initial Results from Pivotal Phase 3 PRESERVE 1 Trial in Colorectal Cancer Expected in February 2023; Positive Results Would Initiate Regulatory Interactions for Label Expansion - - Five Clinical...
G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (PFS) Data Expected in Mid-2023
04 janv. 2023 06h30 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided an initial update on PRESERVE 3, an ongoing...
G1 Therapeutics to Participate in the 41st Annual J.P. Morgan Conference
03 janv. 2023 14h00 HE
|
G1 Therapeutics
RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that on January 11, 2023, at 1:30 PM PST,...